| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_440b3059c9bcd1d85fd383f9b2ae1b40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73d55b44219a84c850812a4488def924 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2017-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f29f57f6714b85b5f8acf6c25cd083ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f5ea2f2329eb1aba3a6883c1e39f28c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bedf4af2139c544d686da2d5cbb6e83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_797f3c3941f6f3f5f0a86e380ff61422 |
| publicationDate |
2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018369282-A1 |
| titleOfInvention |
Gene-modified lymphocytes expressing chimeric antigen receptor in which production of inflammatory cytokines is inhibited |
| abstract |
With the aim of improving the treatment result of CAR therapy, intended is to provide an effective means for the cytokine release syndrome, as an alternative to the administration of the anti-IL-6 receptor antibody or the like. Together with the target antigen-specific chimeric antigen receptor gene, a first nucleic acid construct which intracellularly producing an siRNA targeting interleukin-6 gene and/or a second nucleic acid construct which intracellularly producing an siRNA targeting tumor necrosis factor α gene are introduced into the target cell, thus preparing the gene-modified lymphocyte expressing chimeric antigen receptor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113574174-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021036246-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021036247-A1 |
| priorityDate |
2017-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |